Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial
Overview
Paper Summary
In a study of patients with type 2 diabetes and chronic kidney disease, combining finerenone and empagliflozin led to better kidney function improvement compared to either drug alone, across a range of baseline kidney risk levels. However, the study only followed participants for six months and further long-term research is needed to confirm lasting benefits and safety.
Explain Like I'm Five
Combining two diabetes medications (finerenone and empagliflozin) may be better than using either one alone for improving kidney function in people with type 2 diabetes and chronic kidney disease, regardless of their initial kidney risk level.
Possible Conflicts of Interest
The study was funded by Bayer AG, the manufacturer of finerenone. Several authors reported financial ties to pharmaceutical companies, including Bayer, involved in diabetes and kidney disease treatments.
Identified Limitations
Rating Explanation
This is a well-designed study with a large sample size and important clinical implications. Although the short follow-up duration and strict inclusion criteria limit generalizability to some extent, the findings about consistent benefits across different levels of kidney risk remain valuable.
Good to know
This is the Starter analysis. Paperzilla Pro fact-checks every citation, researches author backgrounds and funding sources, and uses advanced AI reasoning for more thorough insights.
Explore Pro →